The risks of sharing your DNA with online companies aren’t a future concern. They’re here now
By Nila Bala,
Los Angeles Times
| 10. 21. 2024
Turmoil at 23andMe, a company offering popular at-home DNA testing, has upset the industry. Following the resignation of every independent member of the company’s board of directors, its chief executive, Anne Wojcicki, expressed openness to selling the company and its database of around 15 million customers, raising concerns about the misuse of genetic data.
Although Wojcicki has since said she is focused on taking 23andMe private, the data-sharing risks raised by DNA testing and matching companies are already here. A class-action lawsuit filed in August alleges that the operator of GEDmatch.com, a genealogy site that claims to have a database of more than 1 million members, has been sharing users’ information with Facebook. This revelation should alarm us all.
GEDmatch stands apart from companies such as 23andMe. It’s an open, crowdsourced database that anyone can search. Founded in 2010, it emerged as a tool for genealogy enthusiasts to upload DNA results and connect with relatives. It gained notoriety when law enforcement officials announced in 2018 that they had used the service to identify the Golden State...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
